Prevention of Nausea and Vomiting after Hysteroscopy with Betahistine

Effect of Oral Betahistine in Reducing Postoperative Nausea and Vomiting Following Hysteroscopic Surgery under General Anesthesia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250630066304N3

Enrollment

Registered

2026-05-20

Start date

2025-08-21

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting (PONV). Other specified complications of surgical and medical care, not elsewhere classified

Interventions

Intervention 1: Intervention group: Oral betahistine tablets (manufactured by Actoverco Company). Patients received a single 16 mg tablet 3 hours before surgery and a single 8 mg tablet 2 hours before

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Female patients who are candidates for elective hysteroscopic surgery Age between 18 and 60 years Written informed consent to participate in the study No history of allergy or sensitivity to betahistine Absence of underlying gastrointestinal, cardiovascular, and respiratory diseases

Exclusion criteria

Exclusion criteria: Uncontrolled diabetes or impaired glucose tolerance Underlying gastrointestinal disease History of PONV and use of antiemetic medications within 24 hours prior to surgery Middle ear disease Pregnancy Obesity with BMI greater than 35 Hypertension

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative nausea and vomiting (PONV). Timepoint: 2, 4, 6, 12, 24, and 48 hours after surgery. Method of measurement: Clinical observation checklist recorded as a binary outcome (yes or no).;Severity of postoperative nausea. Timepoint: 2, 4, 6, 12, 24, and 48 hours after surgery. Method of measurement: ????? ???? ?? ? ?? ??? ??? ?????????? ??? ???? ? ?? ?????????? ?????? ??? ????.	—

Secondary

Measure	Time frame
Postoperative ondansetron consumption. Timepoint: First 48 hours after surgery. Method of measurement: Extracted from patient pharmacological records and reported in milligrams.;Postoperative morphine consumption. Timepoint: First 48 hours after surgery. Method of measurement: Extracted from patient pharmacological records and reported in milligrams.;Adverse effects including dry mouth, headache, itching, and skin rash. Timepoint: 2, 4, 6, 12, 24, and 48 hours after surgery. Method of measurement: Clinical observation checklist recorded as a binary outcome (yes or no).	—

Measure

Time frame

Postoperative ondansetron consumption. Timepoint: First 48 hours after surgery. Method of measurement: Extracted from patient pharmacological records and reported in milligrams.;Postoperative morphine consumption. Timepoint: First 48 hours after surgery. Method of measurement: Extracted from patient pharmacological records and reported in milligrams.;Adverse effects including dry mouth, headache, itching, and skin rash. Timepoint: 2, 4, 6, 12, 24, and 48 hours after surgery. Method of measurement: Clinical observation checklist recorded as a binary outcome (yes or no).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alieh Zamani Kiasari

Mazandaran University of Medical Sciences

Aliehzamani@gmail.com+98 911 353 3146

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026